1. Overview
This document provides important information about the use of GLP-1 receptor agonist medications (including semaglutide, tirzepatide, and related compounds) for patients aged 75 years and older. Please read this document carefully before consenting to treatment.
2. What Are GLP-1 Receptor Agonists?
GLP-1 (Glucagon-Like Peptide-1) receptor agonists are a class of medications originally developed for type 2 diabetes management that have also been approved for chronic weight management. These medications work by mimicking the GLP-1 hormone, which helps regulate appetite, blood sugar levels, and gastric emptying.
3. Age-Specific Considerations
Important: Patients aged 75 and older may face additional risks and considerations when using GLP-1 medications. Your healthcare provider will carefully evaluate your individual risk profile before prescribing.
Specific considerations for older patients include:
- Increased risk of dehydration due to gastrointestinal side effects
- Potential for excessive weight loss and associated muscle mass reduction (sarcopenia)
- Possible interactions with existing medications commonly prescribed for older adults
- Altered kidney function that may affect drug metabolism and clearance
- Increased sensitivity to blood sugar fluctuations
4. Common Side Effects
The following side effects may occur and may be more pronounced in older patients:
- Nausea, vomiting, and diarrhea
- Decreased appetite
- Abdominal pain and bloating
- Constipation
- Dizziness and fatigue
- Headache
5. Serious Risks
Although rare, the following serious adverse events have been reported:
- Pancreatitis (inflammation of the pancreas)
- Gallbladder disease, including gallstones
- Kidney injury, particularly with dehydration
- Hypoglycemia (low blood sugar), especially when combined with other diabetes medications
- Thyroid tumors, including medullary thyroid carcinoma (observed in animal studies)
- Allergic reactions, including anaphylaxis
- Changes in heart rate
6. Contraindications
GLP-1 medications may not be suitable if you have:
- A personal or family history of medullary thyroid carcinoma
- Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
- A history of pancreatitis
- Severe gastrointestinal disease
- End-stage kidney disease
7. Monitoring and Follow-Up
Patients aged 75 and older who are prescribed GLP-1 medications will require:
- More frequent follow-up appointments and check-ins
- Regular monitoring of kidney function, blood sugar, and weight
- Assessment of nutritional status and muscle mass
- Review of all concurrent medications for potential interactions
8. Patient Acknowledgment
By agreeing to this consent, you acknowledge that:
- You have read and understand the risks described in this document
- You have had the opportunity to ask questions about GLP-1 therapy
- You understand that results may vary and are not guaranteed
- You agree to follow your provider's instructions and attend scheduled follow-ups
- You will promptly report any adverse effects to your healthcare provider
9. Contact Us
If you experience any severe side effects or have concerns about your treatment, contact your healthcare provider immediately or call emergency services. For general questions, please contact us through our website.